ClinicalTrials.gg
CompletedNCT06514963Updated Jan 8, 2025

A Trial of HRS-9813 in Healthy Volunteers

A Phase 1 interventional study of HRS-9813 and Placebo in Healthy Volunteers, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this phase Ⅰ study is to evaluate the safety, tolerability and pharmacokinetics of HRS-9813 in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the study procedures and methods, voluntarily participate in the study, comply with study requirements, and sign the written form (ICF);
  2. Male or female aged 18-55 (adult healthy volunteers);
  3. (BMI) between 19 and 26 kg/m2;
  4. Normal (ECG);
  5. Men and women of must agree to take effective methods.

Exclusion criteria

Exclusion Criteria:

  1. Any significant acute or chronic medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study, including active, or history of, urinary stones, urinary tract infection, or intestinal disorder including irritable bowel syndrome;
  2. History or presence of ; participants with a history of basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence within 5 years will be allowed for inclusion;
  3. Seated systolic blood pressure (SBP) of \<90 mmHg or seated diastolic blood pressure (DBP) of \<60 mmHg;
  4. Patients with orthostatic hypotension;
  5. Positive results of surface antigen, antibody, syphilis antibody and antibody.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    single ascending dose (SAD) cohorts

    Subjects will be assigned to one of 5 planned dose cohorts and receive single dose of HRS-9813 or placebo

    Drug: HRS-9813 · Drug: Placebo

  • Experimental
    multiple ascending dose (MAD) cohorts

    Subjects will be assigned to one of 3-4 planned dose cohorts and receive multiple doses of HRS-9813 or placebo

    Drug: HRS-9813 · Drug: Placebo

Interventions

  • Specified dose on specified days

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Safety: incidence of adverse event (AE), serious adverse event (SAE)

    Time frame: 7 days (SAD), 14 days (MAD)

Secondary outcomes

  1. PK parameter of HRS-9813: Area under the concentration time curve (AUC)

    Time frame: Days 1-9

  2. PK parameter of HRS-9813: Maximum Plasma Concentration (Cmax)

    Time frame: Days 1-9

  3. PK parameter of HRS-9813: Time to maximum plasma concentration (Tmax)

    Time frame: Days 1-9

  4. PK parameter of HRS-9813: Half-life (t1/2)

    Time frame: Days 1-9

  5. PK parameter of HRS-9813: Apparent clearance (CL/F)

    Time frame: Days 1-9

  6. PK parameter of HRS-9813: Apparent volume of distribution (Vz/F)

    Time frame: Days 1-9

  7. PK parameter of HRS-9813: Accumulation ratio (Racc)

    Time frame: Days 1-9

  8. PK parameter of HRS-9813: Cumulative amount excreted (Ae) in the urine

    Time frame: Days 1-2

  9. PK parameter of HRS-9813: Fractional excretion (fe) in the urine

    Time frame: Days 1-2

  10. PK parameter of HRS-9813: Renal clearance (CLR)

    Time frame: Days 1-2

07

Study locations

1 site
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jan 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 23, 2024
StartActual
Jul 24, 2024
Primary completionActual
Jan 2, 2025
CompletionActual
Jan 2, 2025
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06514963
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Jul 24, 2024
Primary completion
Jan 2, 2025
Completion
Jan 2, 2025
Last update
Jan 8, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9813

Start the discussion